Research programme: second generation farnesyl transferase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: second generation farnesyl transferase inhibitors - Bristol-Myers Squibb

Alternative Names: BMS-316810; Second generation farnesyl transferase inhibitors research programme

Latest Information Update: 20 Mar 2007

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 24 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top